Standard BioTools Bundle
Who owns Standard BioTools now?
A major ownership shift occurred in December 2022 when Casdin Capital and Viking Global led a $250,000,000 recapitalization, reshaping governance after prolonged losses. The firm, founded as Fluidigm in 1999 and rebranded in 2022, focuses on single-cell biology, genomics, and proteomics.
Today (2024–2025) the shareholder mix includes the anchor investors from 2022, public market holders after listing as NASDAQ: LAB, insiders, and institutional funds; the January 2024 all-stock merger with SomaLogic expanded the portfolio and influenced ownership and board composition. See Standard BioTools Porter's Five Forces Analysis
Who Founded Standard BioTools?
Founders and early ownership of Standard BioTools trace to its 1999 founding as Fluidigm by Gajus Worthington and Stephen Quake, both Stanford-affiliated; initial equity concentrated with the founders alongside licensed Quake IP and early technical contributors from Stanford’s microfluidics community.
Founding team
Co-founded in 1999 by Gajus Worthington (engineering) and Stephen Quake (bioengineering), leveraging Stanford microfluidics expertise.
Intellectual property
Quake’s IP was licensed/assigned to the company under typical spinout provisions tied to founder common stock.
Early capitalization
Seed and Series A financing came from life-science VCs and strategic angels, including Alloy Ventures and InterWest Partners in early rounds.
Equity mechanics
Founder and early employee equity followed standard four-year vesting schedules with company repurchase rights on unvested shares.
Investor governance
VC participation included protective provisions, preferred shares, board seats for lead investors, and customary buy-sell clauses.
Founder roles
Worthington served long as CEO, maintaining operational control even as venture dilution reduced founder percentage ownership over the 2000s.
Early ownership evolution set the stage for later public ownership and the Standard BioTools shareholder structure seen in SEC filings; for related market positioning see Target Market of Standard BioTools.
Key facts on early ownership
Founders held core common equity at inception; venture rounds diluted those stakes while adding institutional governance typical of VC-backed biotech startups.
- Founded in 1999 as Fluidigm by Gajus Worthington and Stephen Quake
- Quake licensed intellectual property and assigned rights to the company
- Early investors included life-science VCs such as Alloy Ventures and InterWest Partners
- Standard founder equity used four-year vesting and repurchase rights; no major public founder disputes reported
Standard BioTools SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Standard BioTools’s Ownership Changed Over Time?
Key events reshaping Standard BioTools ownership include the 2011 IPO, follow-on financings and acquisitions through 2021, the $250 million 2022 recap led by Casdin Capital and Viking Global, and the January 2024 all-stock merger with SomaLogic — each materially shifting institutional stakes, board composition and dilution of founders.
| Year / Event | Ownership Impact | Notable Stakeholders |
|---|---|---|
| 2011 IPO (NASDAQ) | Raised ~$54 million; broadened institutional base; post-IPO market cap ~$300 million | Mutual funds, life-science specialist institutional investors |
| 2014–2021 Follow‑ons & Acquisitions | Founders/early VCs diluted via follow-ons, secondaries; public institutions grew | DVS Sciences acquisition added specialized investor interest (CyTOF buyers) |
| Dec 2022 Recapitalization | $250 million strategic investment with convertible preferreds/warrants; governance and board changes | Casdin Capital, Viking Global (anchor holders) |
| Jan 2024 SomaLogic merger | All‑stock combination; former SomaLogic holders received a substantial minority; registers merged | Baillie Gifford, Viking, Casdin, other life‑science managers |
| 2024–2025 SEC / 13F filings | Public index funds hold material passive positions; concentrated active holders influence strategy | BlackRock, Vanguard, State Street, ARK Invest, Baillie Gifford, Casdin, Viking |
Current shareholder structure reflects significant institutional ownership, anchor private-investor influence from converted preferreds, a diversified passive index-fund base, and modest insider stakes from executives and directors; founder ownership is minimal after multi-year dilution.
Ownership evolution: checkpoints
Two decisive inflection points altered control: the 2022 recapitalization with preferreds and the 2024 SomaLogic all-stock merger, both expanding institutional registers and reshaping governance.
- 2011 IPO broadened institutional investor base and launched public float
- 2022 strategic investment gave Casdin and Viking convertible exposure and board rights
- 2024 merger added SomaLogic holders (Baillie Gifford, others) and improved cash runway
- 2024–2025 filings show BlackRock, Vanguard, State Street as large passive holders alongside life‑science specialists
See additional context on competitive positioning and stakeholder overlaps in Competitors Landscape of Standard BioTools.
Standard BioTools PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Standard BioTools’s Board?
The board of directors of Standard BioTools in 2024–2025 reflects a mix of anchor-investor representatives and independent life-science executives; the CEO sits on the board and the composition emphasizes diagnostic and tools expertise aligned with institutional holders’ interests.
| Director | Affiliation | Role / Notes |
|---|---|---|
| Representative, Casdin Capital | Casdin-related | Anchor investor appointee; recused on related-party matters |
| Representative, Viking Global | Viking-related | Anchor investor appointee; active post-2022 recapitalization |
| Independent director | Life-science tools/diagnostics executive | Chair/committee member; independent-majority on committees |
| Independent director | Industry veteran | Audit/compensation/nom/gov committee member |
| Chief Executive Officer | Executive | Board director; executive voting subject to insider disclosure rules |
Governance follows a one-share–one-vote common-stock structure; preferred instruments issued in the 2022 financing convert on an as-converted basis to common without dual-class supervoting, and no golden shares have been publicly disclosed.
Board and Voting Key Points
Voting control is driven by institutional stake size rather than special voting rights; committees maintain independent majorities with investor reps recused on related matters.
- Board composition includes anchor-investor reps (Casdin, Viking) plus independent life-science leaders
- The company uses standard one-share–one-vote common stock; 2022 preferreds convert on an as-converted basis
- No public record of golden shares or dual-class supervoting; no high-profile proxy fights since the merger
- Committee control: audit, compensation, nom/gov are independent-majority; related-party recusals applied
Institutional holdings (Casdin, Viking and other mutual funds/asset managers) create concentrated voting power; for latest institutional ownership percentages and top holders see SEC filings and the company’s investor relations disclosures and the article Growth Strategy of Standard BioTools.
Standard BioTools Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Standard BioTools’s Ownership Landscape?
Recent changes in Standard BioTools ownership reflect a shift toward institutional concentration and anchor investor influence following restructuring and a transformative merger; liquidity improved while founder and early VC stakes diluted as the cap table broadened through 2024–2025.
| Period | Key Ownership Shift | Notable Data |
|---|---|---|
| 2022–2023 | Recapitalization shifted effective control to strategic investors | Recapitalization: $250,000,000; performance-tied conversion milestones; expanded equity comp |
| 2024 (post-merger) | All-stock merger with SomaLogic altered cap table and increased float | Merger closed Jan 2024; institutional index inclusion rose; operating expense run-rate reduced |
| 2024–2025 | Gradual institutional concentration; legacy holder secondary sales | Trend: higher passive/index stakes; no large buybacks; focus on cash-flow breakeven |
Ownership trends show anchor investor influence alongside rising passive/index ownership and diversified specialist funds; management prioritized integration and product roadmap over buybacks, while founder/early VC stakes continued to dilute as institutional investors increased position sizes.
Recapitalization impact
The $250,000,000 2022–2023 recap stabilized liquidity and shifted effective control toward key investors while tying upside to performance milestones.
Merger-driven cap table change
The January 2024 all-stock merger with SomaLogic broadened the investor base, increased free float, and supported post-merger inclusion in benchmarks and indices.
Institutional ownership
By 2025, analysts observed a drift toward higher institutional concentration typical of life-science tools mid-caps; passive/index holders rose as float increased.
Insider and legacy holder activity
Founder and early VC stakes continued to dilute; legacy SomaLogic holders executed modest secondary sales that slightly rebalanced ownership without triggering control changes.
For detailed ownership breakdowns, top institutional holders in 2025, SEC filings, and how ownership affects governance see the related article: Marketing Strategy of Standard BioTools
Standard BioTools Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Standard BioTools Company?
- What is Competitive Landscape of Standard BioTools Company?
- What is Growth Strategy and Future Prospects of Standard BioTools Company?
- How Does Standard BioTools Company Work?
- What is Sales and Marketing Strategy of Standard BioTools Company?
- What are Mission Vision & Core Values of Standard BioTools Company?
- What is Customer Demographics and Target Market of Standard BioTools Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.